China making big gains in drug R&D jobs state covets
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
Eli Lilly and Co.
Articles
Six faces behind Indianapolis business Twitter handles
Meet the people who tweet for Indianapolis Symphony Orchestra, AAA, Butler University and other local businesses.
Antidepressants linked to narrowed arteries
The study included Eli Lilly and Co. drug Cymbalta, which racked up sales of $3.5 billion last year for the Indianapolis-based drugmaker.
Drugmaker Lilly launches global service program
Eli Lilly and Co. is starting a service program that sends employees around the world to help developing communities and learn about other cultures, as the drugmaker looks to international markets.
Demographic shift steers Lilly’s Asian operations
China remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic growth.
Drugmakers call off animal-health deal, possible asset sale
Drugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies considered selling.
Regulators delay approval of Lilly’s Alzheimer’s screen
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
PROXY CORNER: Eli Lilly and Co.
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Trade agency to probe Lilly’s infringement claim
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
Lechleiter: After the deluge, we’ll be fine
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
Lilly agrees to buy European animal health company
Elanco, the animal health division of Eli Lilly and Co., has agreed to acquire Jannsen Animal Health, a subsidiary of New Jersey-based Johnson & Johnson, pending regulatory approval. Financial terms of the deal were not disclosed.
Lilly suffers another bruise from Novo
The failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the highly touted diabetes drug.
Lilly’s Bydureon falls short of competitor in study
Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study.
UPDATE: Bioanalytical researcher opening lab in Indianapolis
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
North of South development to start this summer
Now that financing for Buckingham Cos.’ massive project has the city’s blessing, the local developer is turning its full attention to construction of the 14-acre, mixed-use complex.
UPDATE: Lilly settles pollution suit for $337,500
A complaint filed Wednesday by the U.S. government says Lilly’s plant on South Harding Street is emitting high levels of acetonitrile and methanol, considered hazardous air pollutants by the EPA.
Eli Lilly neuroscience chief resigns
David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.
Lilly looks to double pipeline size again
Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.
Emerging markets give Lilly hope in patent crunch
In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
Lilly names new head of cancer drug business
Eli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.